Download PDF
Diabetologie und Stoffwechsel 2010; 5(4): R47-R64
DOI: 10.1055/s-0030-1247455
DuS-Refresher

© Georg Thieme Verlag KG Stuttgart ˙ New York

Sekundäre Diabetesformen / Typ-3-Diabetes

M. Hummel1
  • 1Institut für Diabetesforschung des Helmholtz-Zentrum München & Forschergruppe Diabetes der TU München & Klinik für Endokrinologie · Diabetologie und Suchtmedizin · Klinikum Schwabing · Klinikum München GmbH
Further Information

Publication History

Publication Date:
17 August 2010 (online)

Also available at
    Permissions and Reprints

Einleitung

Diagnostisch und therapeutisch unterscheiden sich die sekundären Diabetesformen zum Teil erheblich von den häufigen Formen des Diabetes, dem Typ-1-Diabetes, dem Typ-2-Diabetes und dem Gestationsdiabetes. Da oftmals eine kausale Therapie möglich ist, kommt neben der korrekten Differenzialdiagnose dem Wissen um die Spezifika dieser Diabetesformen eine wichtige Bedeutung zu. Ziel dieser Übersicht ist es, einige ausgewählte Formen des sekundären Diabetes hinsichtlich Pathogenese, Diagnostik und Therapie darzustellen. 

Literatur

  • 1 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1197
    Google Scholar
  • 2 Fajans S S, Bell G I, Polonsky K S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.  NEJM. 2001;  345 971-980
    CrossrefGoogle Scholar
  • 3 Stumvoll M, Stefan N, Fritsche A et al. Diabetes mellitus. In: Lehnert H, Hrsg. Rationelle Diagnostik und Therapie in Endokrinologie, Stoffwechsel und Diabetes. Stuttgart: Thieme; 2009: 335–379
    Google Scholar
  • 4 Hummel M, Vasseur F, Mathieu C et al. Two caucasian families with the hepatocyte nuclear factor-1alpha mutation Y218C.  Exp Clin Endocrinol Diabetes. 2007;  115 62-64
    Article in Thieme ConnectGoogle Scholar
  • 5 Moran A, Dunitz J, Nathan B et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.  Diabetes Care. 2009;  32 1626-1631
    CrossrefPubMedGoogle Scholar
  • 6 Moran A, Pekow P, Grover P Cystic Fibrosis Related Diabetes Therapy Study Group et al.,. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.  Diabetes Care. 2009;  32 1783-1788
    CrossrefPubMedGoogle Scholar
  • 7 Rizza R A, Mandarino L J, Gerich J E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.  J Clin Endocrinol Metab. 1982;  54 131-138
    CrossrefGoogle Scholar
  • 8 Biering H, Knappe G, Gerl H et al. [Prevalence of diabetes in acromegaly and Cushing’s disease].  Acta Medica Austriaca. 2000;  27 27-31
    CrossrefGoogle Scholar
  • 9 Arnaldi G, Mancini T, Polenta B et al. Cardiovascular risk in Cushing’s syndrome.  Pituitary. 2004;  7 253-256
    CrossrefGoogle Scholar
  • 10 Newell-Price J, Bertagna X, Grossman A B et al. Cushing’s syndrome.  Lancet. 2006;  367 1605-1617
    CrossrefPubMedGoogle Scholar
  • 11 Findling J W, Raff H. Cushing’s Syndrome: important issues in diagnosis and management.  J Clin Endocrinol Metab. 2006;  91 3746-3753
    CrossrefPubMedGoogle Scholar
  • 12 Whitworth J A, Williamson P M, Mangos G et al. Cardiovascular consequences of cortisol excess.  Vasc Health Risk Manag. 2005;  1 291-299
    CrossrefGoogle Scholar
  • 13 Colao A, Auriemma R S, Galdiero M et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.  J Clin Endocrinol Metab. 2009;  94 3746-3756
    CrossrefGoogle Scholar
  • 14 Ali O, Banerjee S, Kelly D F et al. Management of type 2 diabetes mellitus associated with pituitary gigantism.  Pituitary. 2007;  10 359-364
    CrossrefGoogle Scholar
  • 15 Møller N, Jørgensen J O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.  Endocr Rev. 2009;  30 152-177
    CrossrefPubMedGoogle Scholar
  • 16 Kasayama S, Otsuki M, Takagi M et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.  Clin Endocrinol (Oxf). 2000;  52 549-555
    CrossrefGoogle Scholar
  • 17 Resmini E, Minuto F, Colao A et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.  Acta Diabetol. 2009;  46 85-95
    CrossrefGoogle Scholar
  • 18 Yavuz D G, Yüksel M, Deyneli O et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.  Clin Endocrinol (Oxf). 2004;  61 515-521
    CrossrefGoogle Scholar
  • 19 Gupta A K, Dahlof B, Dobson J Anglo-Scandinavian Cardiac Outcomes Trial Investigators et al.,. Determinants of new-onset diabetes among 19 257 ypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.  Diabetes Care. 2008;  31 982-988
    CrossrefGoogle Scholar
  • 20 Elliott W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 201-207
    CrossrefGoogle Scholar
  • 21 NAVIGATOR Study Group . Effect of valsartan on the incidence of diabetes and cardiovascular events.  N Engl J Med. 2010;  362 1477-1490
    CrossrefGoogle Scholar
  • 22 Basile J N. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.  Int J Clin Pract. 2009;  63 656-666
    CrossrefGoogle Scholar
  • 23 Andersohn F, Schade R, Suissa S et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.  Am J Psychiatry. 2009;  166 591-598
    CrossrefGoogle Scholar
  • 24 De Hert M, Schreurs V, Vancampfort D et al. Metabolic syndrome in people with schizophrenia: a review.  World Psychiatry. 2009;  8 15-22
    CrossrefGoogle Scholar
  • 25 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
    CrossrefGoogle Scholar
  • 26 Toro C, Jacobowitz D M, Hallett M. Stiff-Man Syndrome.  Sem Neurol. 1994;  14 154-158
    Article in Thieme ConnectGoogle Scholar
  • 27 Blum P, Jankovic J. Siff-Person Syndrome. An Autoimmune Disease.  Mov Disord. 1991;  6 2-20
    CrossrefGoogle Scholar
  • 28 Solimena M, Folli F, Aparisi R et al. Autoantibodies to GABA-ergic Neurones and Pancreatic Beta Cells in Stiff-Man Syndrome.  N Engl J Med. 1990;  322 1555-1560
    CrossrefGoogle Scholar
  • 29 Baekkeskov S, Aanstoot H J, Christgau S et al. Identification of the 64 k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamatic acid decarboxylase.  Nature. 1990;  347 151-156
    CrossrefGoogle Scholar
  • 30 Hummel M, Durinovic-Bello I, Bonifacio E et al. Humoral and Cellular Immune Parameters before and during immunsuppressive therapy of a patient with Stiff-Man Syndrom and IDDM.  J Neurol Neurosurg Psychiatry. 1998;  65 204-208
    CrossrefGoogle Scholar
  • 31 Rohrer T R, Hennes P, Thon A DPV Initiative et al.,. Down’s syndrome in diabetic patients aged < 20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes.  Diabetologia. 2010;  53 1070-1075
    CrossrefGoogle Scholar

PD Dr. M. Hummel

Institut für Diabetesforschung des Helmholtz-Zentrum München & Forschergruppe Diabetes der TU München & Klinik für Endokrinologie · Diabetologie und Suchtmedizin · Klinikum Schwabing · Klinikum München GmbH

Kölner Platz 1

80804 München

Email: Michael.Hummel@lrz.uni-muenchen.de